Science Journal of Clinical Medicine

| Peer-Reviewed |

Papillary Thyroid Carcinoma During Etanercept Therapy in a Patient with Psoriatic Arthritis

Received: 13 August 2015    Accepted: 24 August 2015    Published: 02 September 2015
Views:       Downloads:

Share This Article

Abstract

Potential for developing malignancies with Tumor necrosis alpha blockers (Anti-TNFα) in romatologic diseases is an important question in our minds, contrary to the proved efficacy of them. To our knowledge, yet no case report has been established about papillary thyroid carcinoma during etanercept therapy for psoriatic arthritis. Here we reported a patient who was diagnosed as papillary thyroid carcinoma while she was using etanercept for psoriatic arthritis. She had medical history for familial trait of carcinoma. Radioactive iodine therapy was administered after the surgery. We preferred to stop etanercept therapy and there was no increase in clinical and laboratory disease activity.

DOI 10.11648/j.sjcm.20150405.13
Published in Science Journal of Clinical Medicine (Volume 4, Issue 5, September 2015)
Page(s) 93-95
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Anti-TNFα, Etanercept, Psoriasis, Papillary Thyroid Carcinoma

References
[1] Georgakopoulou EA, Andreadis D, Arvanitidis E, Loumou P. Biologic agents and oral diseases--an update on clinical applications. Acta dermatovenerologica Croatica: ADC. 2013; 21: 24-34.
[2] Tobiás B, Halászlaki C, Balla B et al. Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer. Pathol Oncol Res. 2015 Aug 11. [Epub ahead of print]
[3] Nikiforov YE. Thyroid carcinoma: molecular pathways and yherapeutic targets. Mod Pathol. 2008; 21(2):37-43.
[4] Mitsiades CS, Poulaki V, Mitsiades N. The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. J. Endocrinol. 2003 Aug; 178(2): 205-216.
[5] Tsatsoulis A. The role of apoptosis in thyroid disease. Minerva Med. 2002; 93(3): 169-180.
[6] Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population based cohort study in the United Kingdom. Arch Dermatol. 2003; 139: 1425-1429.
[7] Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001; 137:778-783.
[8] Wolfe F, Michaud K. The association of new cases of cancer with biologic therapy. Arthritis Rheum. 2006; 54: 549.
[9] Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and metaanalysis of rare harmful effects in randomized controlled trials. J Am Med Assoc. 2006; 295: 2275-2285.
[10] Okada SK, Siegel JN. Risk of serious infections and malignancies with antiTNF antibody therapy in rheumatoid arthritis. J Am Med Assoc. 2006; 296: 2201-2202.
[11] Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor α blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis & Rheumatism. 2010; 62(8): 2517-2524
[12] Lee JJ, Mann JA, Blauvelt A. Papillary thyroid carcinoma in a patient with severe psoriasis receiving adalimumab. J Am Acad Dermatol. 2011; 64(5): 999-1000.
[13] Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Cohort Study of Malignancies and Hospitalised Infectious Events in Treated and Untreated Patients with Psoriasis and a General Population in the United States. Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14068. [Epub ahead of print].
Author Information
  • Department of Physical Medicine and Rehabilitation, School of Medicine, Giresun University, Giresun, Turkey

  • Physical Medicine and Rehabilitation State Hospital, Giresun, Turkey

Cite This Article
  • APA Style

    Ilker Ilhanli, Necip Guder. (2015). Papillary Thyroid Carcinoma During Etanercept Therapy in a Patient with Psoriatic Arthritis. Science Journal of Clinical Medicine, 4(5), 93-95. https://doi.org/10.11648/j.sjcm.20150405.13

    Copy | Download

    ACS Style

    Ilker Ilhanli; Necip Guder. Papillary Thyroid Carcinoma During Etanercept Therapy in a Patient with Psoriatic Arthritis. Sci. J. Clin. Med. 2015, 4(5), 93-95. doi: 10.11648/j.sjcm.20150405.13

    Copy | Download

    AMA Style

    Ilker Ilhanli, Necip Guder. Papillary Thyroid Carcinoma During Etanercept Therapy in a Patient with Psoriatic Arthritis. Sci J Clin Med. 2015;4(5):93-95. doi: 10.11648/j.sjcm.20150405.13

    Copy | Download

  • @article{10.11648/j.sjcm.20150405.13,
      author = {Ilker Ilhanli and Necip Guder},
      title = {Papillary Thyroid Carcinoma During Etanercept Therapy in a Patient with Psoriatic Arthritis},
      journal = {Science Journal of Clinical Medicine},
      volume = {4},
      number = {5},
      pages = {93-95},
      doi = {10.11648/j.sjcm.20150405.13},
      url = {https://doi.org/10.11648/j.sjcm.20150405.13},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.sjcm.20150405.13},
      abstract = {Potential for developing malignancies with Tumor necrosis alpha blockers (Anti-TNFα) in romatologic diseases is an important question in our minds, contrary to the proved efficacy of them. To our knowledge, yet no case report has been established about papillary thyroid carcinoma during etanercept therapy for psoriatic arthritis. Here we reported a patient who was diagnosed as papillary thyroid carcinoma while she was using etanercept for psoriatic arthritis. She had medical history for familial trait of carcinoma. Radioactive iodine therapy was administered after the surgery. We preferred to stop etanercept therapy and there was no increase in clinical and laboratory disease activity.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Papillary Thyroid Carcinoma During Etanercept Therapy in a Patient with Psoriatic Arthritis
    AU  - Ilker Ilhanli
    AU  - Necip Guder
    Y1  - 2015/09/02
    PY  - 2015
    N1  - https://doi.org/10.11648/j.sjcm.20150405.13
    DO  - 10.11648/j.sjcm.20150405.13
    T2  - Science Journal of Clinical Medicine
    JF  - Science Journal of Clinical Medicine
    JO  - Science Journal of Clinical Medicine
    SP  - 93
    EP  - 95
    PB  - Science Publishing Group
    SN  - 2327-2732
    UR  - https://doi.org/10.11648/j.sjcm.20150405.13
    AB  - Potential for developing malignancies with Tumor necrosis alpha blockers (Anti-TNFα) in romatologic diseases is an important question in our minds, contrary to the proved efficacy of them. To our knowledge, yet no case report has been established about papillary thyroid carcinoma during etanercept therapy for psoriatic arthritis. Here we reported a patient who was diagnosed as papillary thyroid carcinoma while she was using etanercept for psoriatic arthritis. She had medical history for familial trait of carcinoma. Radioactive iodine therapy was administered after the surgery. We preferred to stop etanercept therapy and there was no increase in clinical and laboratory disease activity.
    VL  - 4
    IS  - 5
    ER  - 

    Copy | Download

  • Sections